Answers are grounded in this paper and cite their sources.
Processes such as trauma, neurodegenerative disorders, inflammation, and infection may result in spinal cord injury (SCI) and associated neuropathic pain (NP).NP can be difficult to treat and presents an opportunity for advancing research on several issues related to pain, explicitly relating to transcriptional, epigenetic and post-transcriptional research [1].Effective treatment for relief of NPis currently limited; however, direct delivery of either cellular or biologically active therapeutics into the spinal cord may offer an opportunity for treatment of NP.Distinct role of matrix metalloproteinase MMP9 and MMP2 reported recently in causing NP following spinal nerve ligation in a rodent model [2].MMP-9 induces NP through interleukin-1β cleavage and microglia activation at early phase of injury and MMP2 maintains NP through interleukin-1β cleavage and astrocyte activation at later phase of injury.Intrathecal injections of tissue inhibitors TIMP-Abstract: The incidence of traumatic spinal cord injury (SCI) in the United States is around 12,500 new cases per year with a total prevalence of roughly 276,000 patients.Neuropathic pain (NP) is present in 70% of patients suffering from SCI and is a significant concern.Most research focuses on small animal models with small spinal cords (SC) where simple diffusion of a pharmaceutical or biologic treatment can have a substantial effect.However, promising molecular, gene and cell therapies for treating SCI and NP often fail to demonstrate efficacy in the much larger human SC where simple diffusion is not strong enough to bring the therapy into a significant portion of the transverse spinal cord.Additionally, there is a need to visualize, target and control delivery in humans to specific gray matter SC tracts to generate the desired treatment while avoiding undesired side effects.The development of these promising therapies, however, significantly hampered by the lack of a platform for targeted delivery of therapeutics and lack of a relevant large animal model.To address hurdles in delivering agents across the blood/SC barrier, we propose to utilize a CED injection technique that delivers therapeutic agents into neural tissue using a positive pressure gradient that expands the interstitial space and increases fluid penetrance; we have successfully employed CED to overcome limitations of drug delivery in the brain.From clinical perspective, evidence makes it clear that miRNAs may manipulate cell state and molecular processes in order to enhance functional recovery following SCI and alleviate NP.This review contains the extensive history of the use of modeling CED in the spinal cord and understanding the role of siRNA, miRNA, TIMP therapies and limitations if any.This knowledge can serve as a foundation in the development of minimally invasive CED platforms for the delivery of therapeutics into targeted regions of the SC for the attenuation and repair of SCI induced NP.
No takes yet. Share an insight, caveat, or question.
A 2017 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: